US PTAB Patent Cases
5,620 decisions indexed
Page 28 of 188 · 5,620 total
Snap Inc. et al. v.Nokia Technologies Oy
Snap Inc. petitions the PTAB to invalidate Nokia’s ’701 video‑coding patent, asserting obviousness over Murashita, Marpe, and Yu. The petition targets all 20 claims and seeks their cancellation.
MWE Investments, LLC et al. v.Champion Power Equipment, Inc.
MWE Investments and Champion Power Equipment settled their IPR over U.S. Patent 11,905,895 and jointly requested that the settlement be kept confidential under 35 U.S.C. §317(b). The petition seeks withdrawal from the proceeding and confidentiality for the agreement.
MWE Investments, LLC et al. v.Champion Power Equipment, Inc.
MWE Investments, Harbor Freight Tools, and Generac, together with Champion Power Equipment, filed a joint request asking the PTAB to keep the settlement agreement (Exhibit 1300) confidential and separate from the IPR file. The request cites statutory confidentiality provisions.
MWE Investments, LLC et al. v.Champion Power Equipment, Inc.
The PTAB granted settlement motions, terminating the IPRs against Harbor Freight Tools USA Inc. and MWE Investments, LLC, while keeping the settlement agreements confidential. Generac Power Systems remains as the sole petitioner in the related IPRs.
MWE Investments, LLC et al. v.Champion Power Equipment, Inc.
Petitioners seek IPR cancellation of all 21 claims of Champion’s dual‑fuel lockout switch patent, arguing obviousness over DuroMax, Elsdon, Parlatore, Hallberg and a lack of structural support for key claim terms.
Taiwan Semiconductor Manufacturing Company Ltd. v.Marlin Semiconductor Ltd. et al.
The PTAB denied institution of an IPR challenge brought by Taiwan Semiconductor Manufacturing Company Ltd. against Marlin Semiconductor Ltd., finding the petitioner failed to demonstrate a reasonable likelihood of prevailing on the merits.
Meta Platforms, Inc. v.Dialect, LLC
Google’s petition to invalidate Dialect’s speech‑interface patent was denied. The Board concluded the petitioner did not show a reasonable likelihood of success on any of the asserted obviousness grounds.
Meta Platforms, Inc. v.Dialect, LLC
Meta Platforms and Dialect have settled their dispute over U.S. Patent 7,398,209. The parties filed a joint motion to stay all deadlines while they finalize the settlement and prepare dismissal filings.
Voltage, LLC et al. v.Shoals Technologies Group, LLC et al.
Voltage, LLC has filed an IPR petition seeking to invalidate Shoals Technologies’ U.S. Patent 12,015,375 covering photovoltaic lead assemblies. The petition alleges obviousness over Machida and combinations with Solon and Kim, and asks the Board to adopt ITC claim constructions.
Meta Platforms, Inc. v.Dialect, LLC
Meta Platforms petitions the PTAB to invalidate claims 1,4,6‑9 of U.S. Patent 7,398,209, alleging obviousness over multiple speech‑recognition and natural‑language prior arts. The petition lists five grounds invoking 35 U.S.C. § 103.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB held that most of Guardant Health’s ’822 patent claims are obvious over prior‑art sequencing methods, cancelling claims 1‑11, 13, and 17‑20, while claim 12 remains patentable.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI seeks to invalidate all 30 claims of Guardant Health’s DNA‑sequencing patent, arguing they are obvious over Kinde, Craig, and NEB Expressions. The petition asserts no claim construction is needed and that discretionary denial is inappropriate.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI petitions to invalidate Guardant Health’s ’699 patent, asserting that all 27 claims are obvious over Kinde and Miner. The petition emphasizes claim constructions that broaden the scope to circulating cellular DNA and argues discretionary denial is improper.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB affirmed Guardant Health's U.S. Patent 11,149,306 covering cell‑free DNA tagging and counting, finding none of the 29 challenged claims unpatentable after Tempus AI's IPR challenge.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI has petitioned the PTAB to invalidate Guardant Health’s 10,689,699 patent covering molecular‑tagging methods for DNA sequencing, arguing the claims are obvious over Kinde, Miner, and Fan. The petition seeks institution of the IPR and cancellation of claims 1‑27.
Tempus AI, Inc. v.Guardant Health Inc.
Guardant Health files an IPR petition seeking to invalidate multiple claims of Foundation Medicine’s ’830 cancer‑sequencing patent, asserting that the claims are obvious over prior‑art methods for targeted enrichment and NGS analysis.
Excelliance Mos Corporation v.Force MOS Technology Co., Ltd.
The PTAB affirmed all nine claims of Force MOS Technology’s ’634 patent after finding Inergy Technology’s IPR unsubstantiated. The Board held that the petitioner failed to prove anticipation or obviousness over Hirler, Shiraishi, and Kobayashi references.
Tempus AI, Inc. v.Guardant Health Inc.
Guardant Health settled its digital sequencing patent dispute with Foundation Medicine for $25 million plus royalties, granting a non‑exclusive license and dismissing all related litigation.
Excelliance Mos Corporation v.Force MOS Technology Co., Ltd.
Force MOS Technology opposes Excelliance's request for Director Review of a discretionary denial to institute an IPR on its MOSFET patent (U.S. 7,629,634). The Board is urged to uphold the Director's final, non‑appealable decision.
Tempus AI, Inc. v.Guardant Health Inc.
The PTAB instituted an inter partes review of Guardant Health’s cfDNA sequencing patent after Foundation Medicine (Petitioner) showed a reasonable likelihood of success on an obviousness ground over several prior‑art references.
Tempus AI, Inc. v.Guardant Health Inc.
TwinStrand Biosciences petitions the PTAB to invalidate Guardant Health’s 11,149,306 patent covering cfDNA sequencing methods, asserting that the claims are obvious over prior art such as Narayan and Schmitt. The petition also alleges examiner misdirection by Guardant. The case is pending institution.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI has filed an IPR petition seeking to invalidate Guardant Health’s U.S. Patent 10,287,631 covering duplex consensus sequencing, arguing that all 23 claims are obvious over Kinde, Craig, and Travers publications.
Excelliance Mos Corporation v.Force MOS Technology Co., Ltd.
Excelliance Mos Corp. seeks Director Review of a Board’s discretionary denial of institution for its IPR against Force MOS Technology’s trench‑MOSFET patent, arguing the denial ignored material prior art and violated statutory rights.
Meta Platforms, Inc. v.Dialect, LLC
Meta Platforms' IPR against Dialect was resolved through a settlement between Dialect and Microsoft, leading the district court to grant a stay of all deadlines. The stay provides a 29‑day window to finalize the settlement and file dismissal papers.
Excelliance Mos Corporation v.Force MOS Technology Co., Ltd.
The USPTO Director denied Excelliance Mos Corporation’s request for Director Review of the decision that denied institution of IPR2025‑01433 covering patent 7,629,634. The denial leaves the original institution denial in place.
Tempus AI, Inc. v.Guardant Health Inc.
Tempus AI has filed an IPR petition challenging Guardant Health’s ’306 patent covering cfDNA sequencing methods. The challenger asserts that all claim elements were disclosed in earlier publications such as Bielas and Vogelstein, rendering the claims obvious. The petition seeks institution of review to invalidate the patent.
Mundra Solar PV Limited v.First Solar, Inc.
Mundra Solar PV Limited has filed an IPR petition challenging all nine claims of First Solar’s 9,666,732 patent, alleging obviousness over Yablonovitch, Kwark, and Batra. The petition seeks institution of the review.
Meta Platforms, Inc. v.Dialect, LLC
Meta Platforms has filed a petition for inter partes review of Dialect’s ’825 patent covering speech‑recognition methods, asserting that the claims are obvious over multiple prior‑art references.
Meta Platforms, Inc. v.Dialect, LLC
Meta Platforms has filed a petition for inter partes review of Dialect’s U.S. Patent 8,015,006, targeting claims 5 and 6. The challenger alleges obviousness over multiple prior‑art speech‑recognition references. The petition seeks institution of the review.
Caption Health, Inc. et al. v.University of British Columbia
The PTAB granted institution for IPR2025-01422, allowing Caption Health to proceed with challenging University of British Columbia's patent. The Board found a reasonable likelihood of prevailing on at least one claim.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.